摘要
目的:基于OpenFDA数据库对玛巴洛沙韦(baloxavirmarboxil)相关不良事件进行挖掘,探索其发生特点及相互关系,并为临床用药提供参考。方法:对OpenFDA数据库中收录的关于玛巴洛沙韦不良事件进行分析,利用报告比值比法(reporting odds ratio,ROR)和贝叶斯置信度递进神经网络法(Bayesian confidence propagation neural network,BCPNN)对其风险信号进行挖掘,并利用医学用语词典(Medical Dictionary for Drug Regulatory Activities,MedDRA)进行系统归类。结果:共获得7 611 798份报告,其中以玛巴洛沙韦为首要怀疑药物的报告数3 920例,筛选获得89个阳性信号。依据系统器官分类(system organ class,SOC)报告数前5位的依次是呼吸、胸部和纵隔疾病,各类检查,心脏疾病,肝胆系统疾病以及胃肠道功能紊乱。贝叶斯网络图显示心脏、呼吸和血液SOC的相互关系较密切。结论:在玛巴洛沙韦临床使用中,应密切关注相关不良事件的发生,尤其是肝功能异常、心脏症状、神经精神症状、出血等,关注不良事件之间的相互关系,及时采取干预措施,保证用药安全。
OBJECTIVE To explore the relationship of adverse drug events(ADEs)and baloxavirmarboxil based upon the OpenFDA database and provide references for clinical dosing.METHODS ADE reports of baloxavirmarboxil were analyzed.Data mining was performed via reporting odds ratio(ROR)and Bayesian confidence propagation neural network(BCPNN)and the results were systematically classified by Medical Dictionary for Drug Regulatory Activities(MedDRA).RESULTS Among a total of 7611798 reports,3920 cases were reported with baloxavirmarboxil as a primary suspected drug and 89 positive signals obtained after screening.Top five system organ class(SOC)reports were respiratory,chest and mediastinal diseases,miscella⁃neous examinations,heart diseases,hepatobiliary disorders and gastrointestinal dysfunction.Bayesian network suggested that SOCs of heart,respiratory system and blood system were correlated closely.CONCLUSION During clinical dosing of baloxavir⁃marboxil,liver dysfunction,cardiac symptoms,neuropsychiatric symptoms and hemorrhage should be closely monitored.Timely measures are implemented for ensuring drug safety.
作者
张翠翠
曹波
张镭
金蛟
庞炜
安金兵
ZHANG Cuicui;CAO Bo;ZHANG Lei;JIN Jiao;PANG Wei;AN Jinbing(Department of Pharmacy,China-Japan Friendship Hospital,Beijing 100029,China;Department of Health Informatics&Management,School of Health Humanities,Peking University,Beijing 100191,China;School of Statistics,Beijing Normal University,Beijing 100875,China;Department of Physiology&Pathophysiology,School of Basic Medical Sciences,Peking University,Bei-jing 100191,China)
出处
《中国医院药学杂志》
CAS
北大核心
2024年第16期1903-1908,共6页
Chinese Journal of Hospital Pharmacy
基金
北京市自然科学基金面上项目(编号:7212057)
国家自然科学基金面上项目(编号:11771048)。